Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Susanne Isfort & Tim H Brümmendorf. (2018) Bosutinib in chronic myeloid leukemia: patient selection and perspectives. Journal of Blood Medicine 9, pages 43-50.
Read now
Read now
Radhamani Kannaiyan & Daruka Mahadevan. (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Review of Anticancer Therapy 18:12, pages 1249-1270.
Read now
Read now
Articles from other publishers (9)
Jing Huang, Juanjuan Cai, Qingqing Ye, Qiaoying Jiang, Huan Lin & Lun Wu. (2023) Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study. BMJ Open 13:8, pages e071456.
Crossref
Crossref
Sankha Bhattacharya, Vipan Kumar Parihar, Neeraj Singh, Ketan Hatware, Amit Page, Mayank Sharma, Mahendra Kumar Prajapati, Abhishek Kanugo, Datta Pawde, Saurabh Maru, Girdhari Lal Gupta & Sunil Kanvinde. (2023) Targeted delivery of panitumumab-scaffold bosutinib-encapsulated polycaprolactone nanoparticles for EGFR-overexpressed colorectal cancer. Nanomedicine 18:9, pages 713-741.
Crossref
Crossref
Shiyong Xin, Xianchao Sun, Liang Jin, Zhen Zhou, Xiang Liu, Weiyi Li, Wangli Mei, Jiaxin Zhang, Bihui Zhang, Xudong Yao, Liqing Zhou & Lin Ye. (2022) Identifying the Potential Role and Prognostic Value of the Platelet-Derived Growth Factor Pathway in Kidney Renal Clear Cell Carcinoma. Journal of Oncology 2022, pages 1-20.
Crossref
Crossref
Ziyao Li, Shiyong Xin, Shuanbao Yu, Jing Liang & Xuepei Zhang. (2022) Prognostic Signatures and Therapeutic Value Based on the Notch Pathway in Renal Clear Cell Carcinoma. Oxidative Medicine and Cellular Longevity 2022, pages 1-37.
Crossref
Crossref
Ankit Srivastava, Sandhya Rai, Deepa Bisht, Manisha Sachan, Bimal Prasad Jit & Sameer Srivastava. 2022. Protein Kinase Inhibitors. Protein Kinase Inhibitors
361
391
.
Roberto Latagliata, Immacolata Attolico, Malgorzata Monika Trawinska, Isabella Capodanno, Mario Annunziata, Chiara Elena, Luigiana Luciano, Monica Crugnola, Micaela Bergamaschi, Massimiliano Bonifacio, Claudia Baratè, Endri Mauro, Gianni Binotto, Nicola Sgherza, Chiara Aguzzi, Barbara Monteleone, Federica Sorà, Giovanni Caocci, Debora Luzi, Elena Mariggiò, Luigi Scaffidi, Daniele Cattaneo, Antonella Gozzini, Ambra Di Veroli, Elisabetta Abruzzese, Sara Galimberti, Alessandra Iurlo, Giorgina Specchia & Massimo Breccia. (2021) Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Hematological Oncology 39:3, pages 401-408.
Crossref
Crossref
Xiangyu Che, Xiaochen Qi, Yingkun Xu, Qifei Wang & Guangzhen Wu. (2021) Genomic and Transcriptome Analysis to Identify the Role of the mTOR Pathway in Kidney Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance. Oxidative Medicine and Cellular Longevity 2021, pages 1-28.
Crossref
Crossref
Liza BotrosMD.MD., Manon C. A. PronkPhD.PhD., Jenny JuschtenMD.MD., John Liddle, Sofia K. S. H. Morsing, Jaap D. van BuulPhD.PhD., Robert H. Bates, Pieter R. TuinmanMD. PhD.MD. PhD., Jan S. M. van Bezu, Stephan HuveneersPhD.PhD., Harm Jan BogaardMD. PhD.MD. PhD., Victor W. M. van HinsberghPhD.PhD., Peter L. HordijkPhD.PhD. & Jurjan AmanMD. PhD.MD. PhD.. (2020) Bosutinib prevents vascular leakage by reducing focal adhesion turnover and reinforcing junctional integrity. Journal of Cell Science.
Crossref
Crossref
Masaoki Ito, Carles Codony-Servat, Jordi Codony-Servat, David Lligé, Imane Chaib, Xiaoyan Sun, Jing Miao, Rongwei Sun, Xueting Cai, Alberto Verlicchi, Morihito Okada, Miguel Angel Molina-Vila, Niki Karachaliou, Peng Cao & Rafael Rosell. (2019) Targeting PKCι-PAK1 signaling pathways in EGFR and KRAS mutant adenocarcinoma and lung squamous cell carcinoma. Cell Communication and Signaling 17:1.
Crossref
Crossref